Form 4: Erasca Inc. Executive Ebun Garner Reports Stock Option Grant

Ebun Garner, General Counsel & Corporate Secretary of Erasca, Inc., reports the acquisition of stock options for 50,000 shares of common stock.

Summary

• On February 13, 2025, Ebun Garner, General Counsel & Corporate Secretary of Erasca, Inc., was granted stock options to purchase 50,000 shares of Erasca's common stock.
• The exercise price of the stock options is $1.63 per share.
• The options vest monthly over a four-year period, commencing on February 13, 2025, contingent upon continuous service to Erasca.
• The options expire on February 12, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance. It's a neutral-positive event.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing them to increase the value of the stock.

Future Outlook

NA

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech industry where long-term growth is a key objective.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options as part of their compensation packages to align executive incentives with shareholder value creation.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term commitment and performance.

Stakeholder Impact

• The stock option grant incentivizes the executive to work towards increasing shareholder value.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Form 4, Erasca, Ebun Garner, insider trading, beneficial ownership, executive compensation